Overview of radiologic efficacy of new treatments

Area of Science:

• Rheumatology and Immunology
• Pharmacology and Therapeutics

Background:

• Biologic therapies, including anakinra, etanercept, infliximab, and leflunomide, are established treatments for various inflammatory conditions.
• Randomized, double-blind trials demonstrate these agents significantly reduce radiographic progression.

Purpose of the Study:

• To address the knowledge gap regarding the relative efficacy of novel biologic treatments.
• To highlight the challenges and limitations in comparing treatment outcomes across different clinical trials.

Main Methods:

• Review of existing randomized, double-blind trials for anakinra, etanercept, infliximab, and leflunomide.
• Discussion of methodological pitfalls inherent in cross-trial comparisons of treatment arms.

Main Results:

• Convincing evidence exists for the reduction in radiographic progression with these new treatments.
• Direct head-to-head comparisons between these agents have not been conducted, precluding definitive efficacy ranking.

Conclusions:

• While individual trials show efficacy, the comparative effectiveness of anakinra, etanercept, infliximab, and leflunomide is not established.
• Methodological challenges complicate indirect comparisons, underscoring the need for future head-to-head studies.